Meyenberg International Group

Meyenberg International Group appears to be an active business and market development consultancy rather than a biotech, pharma, or healthcare operating company. Based on its website and third-party references, it provides market development, business development, international trade support, product registration assistance, and go-to-market execution for companies expanding across Mexico, Canada, the United States, and Latin America. The firm has been publicly cited for supporting Avivagen’s expansion of OxC-beta Livestock in Mexico and other Latin American markets, suggesting experience in animal health and feed-adjacent commercialization. However, there is no evidence that Meyenberg International Group itself develops therapeutics, operates a proprietary clinical pipeline, or runs drug discovery programs. It is best characterized as a cross-border commercialization and market-entry advisory firm with some exposure to life-science-related clients rather than a life sciences company in its own right.